Exhibit 10.31
LEAK-OUT AGREEMENT
August __, 2022
This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with an understanding by and between Palisade Bio, Inc., a Delaware corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”).
Reference is hereby made to (a) the Underwriting Agreement, dated August __, 2022, by and among the Company and Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the several underwriters named therein (the “Underwriting Agreement”) in connection with the follow-on public offering (the “Offering”) by the Company, pursuant to which the Holder and certain other purchasers acquired (i) shares of voting common stock (“Common Stock”) of the Company (“Shares”), (ii) Series B Convertible Preferred Stock of the Company (the “Preferred Shares”), and (iii) warrants of the Company to purchase Shares (the “Common Warrants,” and together with the Shares and Preferred Shares, the “Securities”) and (b) the registration statement on Form S-1 (File No. 333-265769) (“Registration Statement”). Capitalized terms not defined herein shall have the meaning as set forth in the Underwriting Agreement, unless otherwise set forth herein.
The Holder agrees solely with the Company that from the pricing date of the Offering that the Underwriting Agreement is entered into by and between the Company and Ladenburg and ending at 4:00 pm (New York City time) on August __, 2022 (such period, the “Restricted Period”), neither the Holder, nor any affiliate of such Holder which (x) had or has knowledge of the transactions contemplated by the Underwriting Agreement, (y) has or shares discretion relating to such Holder’s investments or trading or information concerning such Holder’s investments, including in respect of the Securities, or (z) is subject to such Holder’s review or input concerning such affiliate’s investments or trading (together, the “Holder’s Trading Affiliates”), collectively, shall sell, dispose or otherwise transfer, directly or indirectly, (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions) on any Trading Day during the Restricted Period (any such date, a “Date of Determination”), shares of Common Stock, or shares of Common Stock underlying any Common Stock Equivalents, as well as the shares of Common Stock issuable upon conversion of the Preferred Shares and upon exercise of the Common Warrants, in an amount representing more than, when measured at any given point during the applicable Date of Determination, ___%1 of the cumulative trading volume of the Common Stock for such date (which cumulative trading volume shall include pre-market, market and post-market trading volume for such date) as reported by Bloomberg, LP (“Leak-Out Percentage”), provided that, for purposes of clarity, the Leak-Out Percentage of the cumulative trading volume of the Common Stock on the applicable Date of Determination applies at each moment during such Date of Determination.
Notwithstanding anything herein to the contrary, during the Restricted Period, the Holder may, directly or indirectly, sell or transfer all, or any part, of any “restricted securities” (as defined in Rule 144) to any Person (an “Assignee”) in a transaction which does not need to be reported on the consolidated tape on the Company’s principal Trading Market, without complying with (or
1 | Pro rata portion of 30% among investors executing Leak-Out Agreements, based on the aggregate amount to be paid by each such investor for the Class A Units and/or Class B Units |